Assertio and Garda Agree to Delay Acquisition Offer to May 14, 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 08 2026
0mins
Should l Buy ASRT?
Assertio Holdings has reached a mutual agreement with Garda Therapeutics to delay the launch of the previously announced tender offer to acquire all outstanding shares of Assertio to May 14, 2026. As previously announced on May 4, 2026, Assertio has entered into an amended and restated merger agreement to be acquired by Garda for $21.80 per share in cash, or total cash consideration of $153.2M. The Company expects to file a Schedule 14D-9 in connection with the tender offer on May 14, 2026. In addition, Assertio will delay the launch of the previously announced tender offer for all outstanding Convertible Senior Notes until May 14, 2026.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ASRT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ASRT
Wall Street analysts forecast ASRT stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 23.320
Low
35.00
Averages
40.00
High
45.00
Current: 23.320
Low
35.00
Averages
40.00
High
45.00
About ASRT
Assertio Holdings, Inc. is a pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investor Rights Law Firm Investigates Multiple Companies
- Insider Trading Investigation: Halper Sadeh LLC is investigating Select Medical Holdings Corporation's sale to a consortium led by its executives and directors for $16.50 per share in cash, which may infringe on shareholder rights.
- UniFirst Acquisition Details: UniFirst Corporation is being sold to Cintas Corporation for $155.00 in cash and 0.7720 shares of Cintas stock per UniFirst share, potentially limiting superior competing offers.
- Centessa Pharmaceuticals Deal: Centessa Pharmaceuticals plc is selling to Eli Lilly for $38.00 in cash per share plus a non-transferable contingent value right that could yield up to $9.00 upon achieving certain milestones, prompting shareholders to consider their rights.
- Assertio Sale Dynamics: Assertio Holdings, Inc. is being sold to Garda Therapeutics for $18.00 per share in cash along with a contingent value right, with Halper Sadeh LLC potentially seeking increased consideration and additional disclosures for shareholders.
See More
Healthcare Stocks Rise 0.8% on NYSE Healthcare Index
- Healthcare Sector Recovery: On Wednesday afternoon, the NYSE Healthcare Index rose by 0.8%, indicating a gradual restoration of investor confidence in the healthcare sector, likely driven by an overall improvement in market sentiment.
- Market Rebound Signs: The increase in healthcare stocks suggests that despite economic uncertainties, investors remain optimistic about the long-term growth potential of the healthcare industry, particularly in areas like drug development and medical technology innovation.
- Increased Investor Attention: As the healthcare sector continues to evolve, heightened investor interest may lead to increased capital inflows into this area, further driving stock prices upward.
- Optimistic Industry Outlook: The growth potential of the healthcare sector is attracting more investor attention, especially against the backdrop of rising global health demands, with expectations for increased investments to support innovation and expansion in the future.
See More
Ademi LLP Investigates Assertio's Transaction Compliance
- Shareholder Rights Investigation: Ademi LLP is investigating Assertio (NASDAQ:ASRT) for potential breaches of fiduciary duty and other legal violations related to its transaction with Zydus, aiming to protect shareholder interests.
- Cash Acquisition Terms: Assertio shareholders will receive $23.50 per share in cash, totaling approximately $166.4 million, reflecting the company's valuation in the merger context.
- Competitive Transaction Restrictions: The transaction agreement imposes significant penalties on Assertio for accepting competing bids, which may undermine the best interests of shareholders by limiting their options.
- Board Responsibility Review: We are examining whether Assertio's board of directors is fulfilling its fiduciary duties to all shareholders, ensuring that their decision-making processes align with the long-term interests of the shareholders.
See More
Assertio and Garda Reach Agreement to Delay Acquisition Launch
- Acquisition Agreement Delay: Assertio and Garda have mutually agreed to postpone the launch of the acquisition tender offer to May 14, 2026, which may affect short-term shareholder decisions and potentially diminish market confidence in the acquisition.
- Cash Acquisition Price: Under the amended merger agreement, Garda will acquire Assertio at $21.80 per share, totaling $153.2 million in cash, a price that may be perceived as insufficiently attractive in the current market environment.
- Convertible Senior Notes Offer Postponed: Assertio has also decided to delay the tender offer for all outstanding Convertible Senior Notes until May 14, 2026, which could influence investors' perceptions of the company's financial stability.
- Future Outlook Uncertainty: The delays in the acquisition and tender offers create uncertainty for Assertio's future development, potentially impacting its competitive position in the oncology market, especially at a critical time when investor attention is heightened.
See More
Garda Therapeutics Raises Acquisition Offer to $21.80 per Share
- Increased Acquisition Offer: Garda Therapeutics has raised its all-cash tender offer for Assertio Holdings to $21.80 per share, valuing the company at approximately $153.2 million, which represents a 21.1% increase over the initial bid, indicating confidence in Assertio's future potential.
- Positive Stock Reaction: Following the announcement, Assertio's shares jumped 17% in early trading, reflecting a positive market response to the revised offer and enhancing investor confidence in the company's value.
- Amended Merger Agreement: The companies entered into an amended merger agreement on May 1 after a “window-shop” process, where Assertio engaged with multiple parties and received a superior proposal, prompting further negotiations with Garda to ensure the best outcome for shareholders.
- Expected Transaction Completion: Under the terms, Garda will acquire all outstanding shares at $21.80 each, with the deal expected to close in the second quarter of 2026, leading to Assertio's delisting from Nasdaq and marking a significant strategic shift for the company.
See More
ASSERTIO: GARDA TO PURCHASE ALL OUTSTANDING SHARES OF CO FOR $21.80 EACH IN CASH UNDER REVISED AGREEMENT TERMS
- Acquisition Announcement: GARDAT has announced its intention to acquire all outstanding shares of COFOR for $21.80 per share in cash.
- Terms of Agreement: The acquisition is being conducted under the terms of an amended agreement.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Insider Trading Investigation: Halper Sadeh LLC is investigating Select Medical Holdings Corporation's sale to a consortium led by its executives and directors for $16.50 per share in cash, which may infringe on shareholder rights.
- UniFirst Acquisition Details: UniFirst Corporation is being sold to Cintas Corporation for $155.00 in cash and 0.7720 shares of Cintas stock per UniFirst share, potentially limiting superior competing offers.
- Centessa Pharmaceuticals Deal: Centessa Pharmaceuticals plc is selling to Eli Lilly for $38.00 in cash per share plus a non-transferable contingent value right that could yield up to $9.00 upon achieving certain milestones, prompting shareholders to consider their rights.
- Assertio Sale Dynamics: Assertio Holdings, Inc. is being sold to Garda Therapeutics for $18.00 per share in cash along with a contingent value right, with Halper Sadeh LLC potentially seeking increased consideration and additional disclosures for shareholders.
See More
Healthcare Stocks Rise 0.8% on NYSE Healthcare Index
- Healthcare Sector Recovery: On Wednesday afternoon, the NYSE Healthcare Index rose by 0.8%, indicating a gradual restoration of investor confidence in the healthcare sector, likely driven by an overall improvement in market sentiment.
- Market Rebound Signs: The increase in healthcare stocks suggests that despite economic uncertainties, investors remain optimistic about the long-term growth potential of the healthcare industry, particularly in areas like drug development and medical technology innovation.
- Increased Investor Attention: As the healthcare sector continues to evolve, heightened investor interest may lead to increased capital inflows into this area, further driving stock prices upward.
- Optimistic Industry Outlook: The growth potential of the healthcare sector is attracting more investor attention, especially against the backdrop of rising global health demands, with expectations for increased investments to support innovation and expansion in the future.
See More
Ademi LLP Investigates Assertio's Transaction Compliance
- Shareholder Rights Investigation: Ademi LLP is investigating Assertio (NASDAQ:ASRT) for potential breaches of fiduciary duty and other legal violations related to its transaction with Zydus, aiming to protect shareholder interests.
- Cash Acquisition Terms: Assertio shareholders will receive $23.50 per share in cash, totaling approximately $166.4 million, reflecting the company's valuation in the merger context.
- Competitive Transaction Restrictions: The transaction agreement imposes significant penalties on Assertio for accepting competing bids, which may undermine the best interests of shareholders by limiting their options.
- Board Responsibility Review: We are examining whether Assertio's board of directors is fulfilling its fiduciary duties to all shareholders, ensuring that their decision-making processes align with the long-term interests of the shareholders.
See More
Assertio and Garda Reach Agreement to Delay Acquisition Launch
- Acquisition Agreement Delay: Assertio and Garda have mutually agreed to postpone the launch of the acquisition tender offer to May 14, 2026, which may affect short-term shareholder decisions and potentially diminish market confidence in the acquisition.
- Cash Acquisition Price: Under the amended merger agreement, Garda will acquire Assertio at $21.80 per share, totaling $153.2 million in cash, a price that may be perceived as insufficiently attractive in the current market environment.
- Convertible Senior Notes Offer Postponed: Assertio has also decided to delay the tender offer for all outstanding Convertible Senior Notes until May 14, 2026, which could influence investors' perceptions of the company's financial stability.
- Future Outlook Uncertainty: The delays in the acquisition and tender offers create uncertainty for Assertio's future development, potentially impacting its competitive position in the oncology market, especially at a critical time when investor attention is heightened.
See More
Garda Therapeutics Raises Acquisition Offer to $21.80 per Share
- Increased Acquisition Offer: Garda Therapeutics has raised its all-cash tender offer for Assertio Holdings to $21.80 per share, valuing the company at approximately $153.2 million, which represents a 21.1% increase over the initial bid, indicating confidence in Assertio's future potential.
- Positive Stock Reaction: Following the announcement, Assertio's shares jumped 17% in early trading, reflecting a positive market response to the revised offer and enhancing investor confidence in the company's value.
- Amended Merger Agreement: The companies entered into an amended merger agreement on May 1 after a “window-shop” process, where Assertio engaged with multiple parties and received a superior proposal, prompting further negotiations with Garda to ensure the best outcome for shareholders.
- Expected Transaction Completion: Under the terms, Garda will acquire all outstanding shares at $21.80 each, with the deal expected to close in the second quarter of 2026, leading to Assertio's delisting from Nasdaq and marking a significant strategic shift for the company.
See More
ASSERTIO: GARDA TO PURCHASE ALL OUTSTANDING SHARES OF CO FOR $21.80 EACH IN CASH UNDER REVISED AGREEMENT TERMS
- Acquisition Announcement: GARDAT has announced its intention to acquire all outstanding shares of COFOR for $21.80 per share in cash.
- Terms of Agreement: The acquisition is being conducted under the terms of an amended agreement.
See More
